Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - SALIX PHARMACEUTICALS LTDFinancial_Report.xls
EX-32.2 - SECTION 906 CFO CERTIFICAITON - SALIX PHARMACEUTICALS LTDdex322.htm
EX-32.1 - SECTION 906 CEO CERTIFICATION - SALIX PHARMACEUTICALS LTDdex321.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - SALIX PHARMACEUTICALS LTDdex312.htm
EX-10.84 - FINISHED PRODUCT MANUFACTURING AND SUPPLY AGREEMENT DATED MARCH 31, 2011 - SALIX PHARMACEUTICALS LTDdex1084.htm
EX-10.80 - LICENSE AGREEMENT DATED FEBRUARY 3, 2011 - SALIX PHARMACEUTICALS LTDdex1080.htm
EX-10.82 - OFFICE LEASE DATED FEBRUARY 14, 2011 - SALIX PHARMACEUTICALS LTDdex1082.htm
EX-10.81 - 2010 AGREEMENT RELATED TO PROGENICS'S MNTX IN-LICENSE - SALIX PHARMACEUTICALS LTDdex1081.htm
EX-10.83 - AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT - SALIX PHARMACEUTICALS LTDdex1083.htm
EX-10.29.1 - SECOND AMENDMENT TO LEASE DATED FEBRUARY 11, 2011 - SALIX PHARMACEUTICALS LTDdex10291.htm
EX-10.68.1 - FIRST AMENDMENT TO RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT - SALIX PHARMACEUTICALS LTDdex10681.htm
10-Q - FORM 10-Q - SALIX PHARMACEUTICALS LTDd10q.htm
EX-3.1 - CERTIFICATE OF INCORPORATION, AS AMENDED - SALIX PHARMACEUTICALS LTDdex31.htm

EXHIBIT 31.1

CERTIFICATION

I, Carolyn J. Logan, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Salix Pharmaceuticals, Ltd.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:  

May 10, 2011

    By:  

/s/ Carolyn J. Logan

       

Carolyn J. Logan

President and Chief Executive Officer